LOGICOR
22.3.2019 15:31:03 CET | Business Wire | Press release
Logicor announces strong financial performance for the year ended 31 December
- Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%).
- Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe.
- EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps).
- LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x.
Capital Structure
In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of unsecured fixed-rate debt in the public capital markets alongside a €750 million unsecured Revolving Credit Facility (‘RCF’).
Through a combination of the bond proceeds, €300 million drawn under the RCF and €207 million of cash, Logicor repaid a portion of the secured, floating-rate facility, allowing us to move to a more flexible, diversified capital structure and increasing our weighted average maturity to 4.4 years.
Development and Expansion
In 2018 we invested €80 million in developing and expanding new logistics space for our customers, with four development projects completing in Italy, Finland, Germany and Romania with a total project cost of €74 million and an average yield on cost of 11%. We have eight further projects under way in Germany (4), Finland (2), UK (1) and Poland (1), with total projected costs of €79 million and a projected average yield on cost of 8%. All of these projects were 100% fully pre-leased before commencement.
Additionally, we have client-led development opportunities consisting of 18 projects that are primarily located in our core markets of Germany and France. These projects would deliver approximately 390,000 sqm of additional GLA with a total projected cost of €292 million.
Commenting on the results, Mo Barzegar, CEO & Chairman
said:
“2018
was a great year for Logicor where we made excellent progress across a
range of strategic initiatives including overall portfolio occupancy
increases, capturing market rental growth and selective portfolio
expansion based on strong customer demand.
With the high-quality of
the assets that we own and operate and the continued excellence
demonstrated by our customer-facing asset management teams across all of
our markets, I am confident that the business is in excellent shape to
continue to deliver strong performance in 2019.”
Simon Clinton, CFO
added:
“Our successful debut capital
markets issuance provides us with a more flexible and diversified
capital structure and demonstrates strong investor support for our
high-quality assets. Additionally, our strong operational results, which
were driven by the combination of our deep customer relationships and
well-located assets, exhibit our ability to generate stable cash flow.”
Results summary
|
As at
|
As at
|
||||||||||
| EPRA Occupancy Rate | 94.4% | n/a | |||||||||
| GLA (million sqm) | 13.6 | 13.5 | |||||||||
| GAV (€ million) | 12,501 |
12,106 |
|||||||||
| NOI (€ million) | 639 | n/a | |||||||||
| LTV | 51% | 52% |
1 Northern Europe includes Austria, Belgium, Germany and Netherlands.
END
About Logicor
Logicor is the largest owner and operator of modern logistics and distribution properties in Europe. As at 31 December 2018 we own a portfolio of 621 high-quality properties with a lettable area of approximately 13.6 million square metres located in key European logistics markets. Logicor is headquartered in London and Luxembourg.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190322005275/en/
Contact:
For further information please contact: Simon Clinton, CFO clinton@logicor.eu +44 (0) 207 198 4973
Courtney Huggins, Treasurer huggins@logicor.eu +44 (0) 203 137 8412
Mark Roberts, Head of Communications roberts@logicor.eu +44 (0) 207 198 2425
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom